Liver function may affect how Weight-Loss drug petrelintide works

NCT ID NCT07682818

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests how the experimental weight-loss drug petrelintide is processed in people with mild to moderate liver impairment compared to those with healthy livers. Researchers will measure drug levels in the blood after a single injection. The goal is to see if liver problems change how the drug behaves, which could guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Petrelintide (ZP8396)
What this could lead to
If petrelintide behaves similarly in people with liver issues, it may be safe to use in a broader population for weight management.
What could go wrong
This is an early-phase, small study (36 people) focused on drug processing, not on weight loss or safety. Results may not predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centrum Badan Klinicznych Piotr Napora Lekarze sp.p.

    RECRUITING

    Wroclaw, Poland, 51-162, Poland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Summit Clinical Research s.r.o.

    RECRUITING

    Bratislava, Bratislava Region, 831 01, Slovakia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Summit Clinical Research s.r.o.

    RECRUITING

    Malacky, Malacky, 901 01, Slovakia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.